SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Global Innovative Platforms completed a Reg A offering and submitted a 15c2-11 application to FINRA while expanding scientific development across multiple parasitic infection detec…
Altus Group U.S. Inc. consented to the inclusion of its real property valuation role in Hines Global Income Trust's June 15, 2026 Form 8-K filing. This consent enables the NAV per …
Elicio Therapeutics reported that its AMPLIFY-7P Phase 2 study of ELI-002 7P failed to meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvan…
enGene announced 54% complete response rate in LEGEND pivotal cohort and plans to initiate a Biologics License Application for detalimogene in the second half of 2026 pending FDA e…
Strategy Inc amended and restated its certificate of designations for Variable Rate Series A Perpetual Stretch Preferred Stock, detailing terms for dividend payments, redemption ri…
ESS Tech received notice from NYSE that its stock failed to meet the $1.00 minimum price requirement, averaging $0.98 over 30 trading days. The company has six months to regain com…
Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, achieving 87% reduction in attacks versus placebo with 62% of patients attack-free. The in vivo CR…
InterDigital filed amended and restated bylaws updating shareholder meeting rules, notice requirements, and electronic participation options. The procedural changes align governanc…
Neumora's Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to meet primary endpoints for major depressive disorder, prompting the company to halt development. The company is …
Alkermes announced that its investigational narcolepsy and idiopathic hypersomnia treatment alixorexton received orphan drug designations from the FDA and European Commission, prov…
Lexeo Therapeutics announced finalization of the SUNRISE-FA 2 pivotal trial protocol for LX2006 in Friedreich ataxia, with first patient enrollment expected by end of Q2 2026 and B…
Elite Pharmaceuticals announced positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug, with the generic product demonstrated as bioequ…
The FDA approved Dexcom Inc.'s Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor for children ages 2 and older who don't use insulin. The integr…
ERock, Inc. (formerly Enchanted Rock, Inc.) filed an amended and restated certificate of incorporation establishing a three-class stock structure with 1.17 billion authorized share…
Perfect Moment's stock will trade on OTCQB under ticker PMNT effective June 15, 2026, following its failure to meet minimum stockholders' equity requirements. The move allows the c…
Traws Pharma deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA, citing mutagenic co…
HF Foods Group Inc. filed a Certificate of Designation establishing Series AA Participating Preferred Stock with a par value of $0.001 per share and dividend rights. The preferred …
MicroVision announced an application to transfer its stock listing from Nasdaq Global Market to Nasdaq Capital Market to obtain additional compliance time for minimum bid price req…
BigBear.ai Holdings increased authorized shares from an unspecified prior amount to 1.001 billion total (1B common, 1M preferred) through a stockholder-approved certificate amendme…
Laser Photonics Corporation regained compliance with Nasdaq Listing Rule 5250(c)(1) on June 12, 2026, after filing its delayed first quarter 2026 Form 10-Q. The company had been no…